NO316977B1 - S-substituerte 11<beta>-benzaldoksim-ostra-4,9-dien-karboksylsyretiolestere, fremgangsmate for deres fremstilling, farmasoytiske preparater inneholdende disse forbindelser, samt anvendelse av forbindelsene til fremstilling av medikamenter og prevensjonsmi - Google Patents

S-substituerte 11<beta>-benzaldoksim-ostra-4,9-dien-karboksylsyretiolestere, fremgangsmate for deres fremstilling, farmasoytiske preparater inneholdende disse forbindelser, samt anvendelse av forbindelsene til fremstilling av medikamenter og prevensjonsmi Download PDF

Info

Publication number: NO316977B1
Authority: NO; Norway
Prior art keywords: benzaldehyde; dien; oxoestra; oxime; carbonyl
Prior art date: 1998-03-03

Application number

NO20004362A

Other languages

English (en)

Norwegian (no)

Other versions

NO20004362D0 (no

NO20004362L (no

Inventor

Walter Elger

Gerd Schubert

Guenther Kaufmann

Sven Ring

Birgit Schneider

Original Assignee

Schering Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-03

Filing date

2000-09-01

Publication date

2004-07-12

2000-09-01 Application filed by Schering Ag filed Critical Schering Ag

2000-09-01 Publication of NO20004362D0 publication Critical patent/NO20004362D0/no

2000-10-31 Publication of NO20004362L publication Critical patent/NO20004362L/no

2004-07-12 Publication of NO316977B1 publication Critical patent/NO316977B1/no

Links

150000001875 compounds Chemical class 0.000 title claims description 51
238000002360 preparation method Methods 0.000 title claims description 15
238000000034 method Methods 0.000 title claims description 11
239000003433 contraceptive agent Substances 0.000 title claims description 7
239000003814 drug Substances 0.000 title claims description 7
229940079593 drug Drugs 0.000 title claims description 6
230000008569 process Effects 0.000 title claims description 6
229940124558 contraceptive agent Drugs 0.000 title claims description 4
239000008194 pharmaceutical composition Substances 0.000 title 1
150000002923 oximes Chemical class 0.000 claims description 50
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 48
150000003839 salts Chemical class 0.000 claims description 15
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 14
125000004432 carbon atom Chemical group C* 0.000 claims description 12
-1 cyano, amino Chemical group 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 10
210000004291 uterus Anatomy 0.000 claims description 8
125000000217 alkyl group Chemical group 0.000 claims description 7
238000006243 chemical reaction Methods 0.000 claims description 7
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 7
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
239000002904 solvent Substances 0.000 claims description 6
239000000262 estrogen Substances 0.000 claims description 5
201000009273 Endometriosis Diseases 0.000 claims description 4
239000000460 chlorine Substances 0.000 claims description 4
238000002657 hormone replacement therapy Methods 0.000 claims description 4
239000000825 pharmaceutical preparation Substances 0.000 claims description 4
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
201000000736 Amenorrhea Diseases 0.000 claims description 3
206010001928 Amenorrhoea Diseases 0.000 claims description 3
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
231100000540 amenorrhea Toxicity 0.000 claims description 3
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 3
229910052794 bromium Inorganic materials 0.000 claims description 3
229910052799 carbon Inorganic materials 0.000 claims description 3
229910052801 chlorine Inorganic materials 0.000 claims description 3
239000011737 fluorine Substances 0.000 claims description 3
229910052731 fluorine Inorganic materials 0.000 claims description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
229910052740 iodine Inorganic materials 0.000 claims description 3
125000000160 oxazolidinyl group Chemical group 0.000 claims description 3
230000002441 reversible effect Effects 0.000 claims description 3
238000002560 therapeutic procedure Methods 0.000 claims description 3
208000005171 Dysmenorrhea Diseases 0.000 claims description 2
206010013935 Dysmenorrhoea Diseases 0.000 claims description 2
206010030247 Oestrogen deficiency Diseases 0.000 claims description 2
206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
150000004675 formic acid derivatives Chemical class 0.000 claims description 2
230000006698 induction Effects 0.000 claims description 2
238000006467 substitution reaction Methods 0.000 claims description 2
150000003512 tertiary amines Chemical class 0.000 claims description 2
239000012038 nucleophile Substances 0.000 claims 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 57
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 50
239000000186 progesterone Substances 0.000 description 25
229960003387 progesterone Drugs 0.000 description 25
230000000694 effects Effects 0.000 description 19
238000002844 melting Methods 0.000 description 18
230000008018 melting Effects 0.000 description 18
238000012360 testing method Methods 0.000 description 18
239000000126 substance Substances 0.000 description 15
239000000243 solution Substances 0.000 description 14
102000005962 receptors Human genes 0.000 description 13
108020003175 receptors Proteins 0.000 description 13
238000005160 1H NMR spectroscopy Methods 0.000 description 12
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
239000000203 mixture Substances 0.000 description 12
241000700198 Cavia Species 0.000 description 11
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
239000005977 Ethylene Substances 0.000 description 9
241001465754 Metazoa Species 0.000 description 9
VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 9
230000035935 pregnancy Effects 0.000 description 9
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 8
238000005481 NMR spectroscopy Methods 0.000 description 8
239000005557 antagonist Substances 0.000 description 8
239000003418 antiprogestin Substances 0.000 description 8
239000000044 progesterone antagonist Substances 0.000 description 8
102000003998 progesterone receptors Human genes 0.000 description 8
108090000468 progesterone receptors Proteins 0.000 description 8
IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
230000027455 binding Effects 0.000 description 7
238000004587 chromatography analysis Methods 0.000 description 7
230000035558 fertility Effects 0.000 description 7
239000005457 ice water Substances 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
239000002244 precipitate Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
230000001270 agonistic effect Effects 0.000 description 6
239000008280 blood Substances 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
229950011093 onapristone Drugs 0.000 description 6
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 5
239000013543 active substance Substances 0.000 description 5
230000002513 anti-ovulatory effect Effects 0.000 description 5
238000002156 mixing Methods 0.000 description 5
230000007935 neutral effect Effects 0.000 description 5
230000027758 ovulation cycle Effects 0.000 description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
150000003180 prostaglandins Chemical class 0.000 description 5
239000003826 tablet Substances 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
235000019439 ethyl acetate Nutrition 0.000 description 4
239000006260 foam Substances 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
239000000700 radioactive tracer Substances 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
230000028327 secretion Effects 0.000 description 4
VKTIONYPMSCHQI-XAGFEHLVSA-N 13,14-dihydro-15-keto-PGF2alpha Chemical compound CCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O VKTIONYPMSCHQI-XAGFEHLVSA-N 0.000 description 3
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000012043 crude product Substances 0.000 description 3
210000000172 cytosol Anatomy 0.000 description 3
239000008298 dragée Substances 0.000 description 3
210000004696 endometrium Anatomy 0.000 description 3
210000000981 epithelium Anatomy 0.000 description 3
229940011871 estrogen Drugs 0.000 description 3
210000004392 genitalia Anatomy 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
238000005259 measurement Methods 0.000 description 3
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
239000003921 oil Substances 0.000 description 3
239000012074 organic phase Substances 0.000 description 3
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000000583 progesterone congener Substances 0.000 description 3
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000013558 reference substance Substances 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000001960 triggered effect Effects 0.000 description 3
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
102000003676 Glucocorticoid Receptors Human genes 0.000 description 2
108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
231100000176 abortion Toxicity 0.000 description 2
206010000210 abortion Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
239000000556 agonist Substances 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
238000011888 autopsy Methods 0.000 description 2
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
210000004246 corpus luteum Anatomy 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
229960003957 dexamethasone Drugs 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
230000002124 endocrine Effects 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
231100000546 inhibition of ovulation Toxicity 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
229960004400 levonorgestrel Drugs 0.000 description 2
230000029860 luteolysis Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229960003248 mifepristone Drugs 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
230000003285 pharmacodynamic effect Effects 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
210000001541 thymus gland Anatomy 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000009466 transformation Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 description 1
PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical class CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
GRNOZCCBOFGDCL-UHFFFAOYSA-N 2,2,2-trichloroacetyl isocyanate Chemical compound ClC(Cl)(Cl)C(=O)N=C=O GRNOZCCBOFGDCL-UHFFFAOYSA-N 0.000 description 1
IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
206010061692 Benign muscle neoplasm Diseases 0.000 description 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
206010027514 Metrorrhagia Diseases 0.000 description 1
201000004458 Myoma Diseases 0.000 description 1
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
244000046052 Phaseolus vulgaris Species 0.000 description 1
235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
229940123788 Progesterone receptor antagonist Drugs 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
235000003846 Ricinus Nutrition 0.000 description 1
241000322381 Ricinus <louse> Species 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
108010085012 Steroid Receptors Proteins 0.000 description 1
101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
239000004015 abortifacient agent Substances 0.000 description 1
231100000641 abortifacient agent Toxicity 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
229940008309 acetone / ethanol Drugs 0.000 description 1
206010000496 acne Diseases 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
102000001307 androgen receptors Human genes 0.000 description 1
108010080146 androgen receptors Proteins 0.000 description 1
230000001548 androgenic effect Effects 0.000 description 1
230000002800 anti-glucocorticoid effect Effects 0.000 description 1
239000011260 aqueous acid Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000006003 cornification Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
229940109275 cyclamate Drugs 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
235000019256 formaldehyde Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
230000003676 hair loss Effects 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
201000010260 leiomyoma Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000009245 menopause Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
230000016548 negative regulation of prostaglandin secretion Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
150000002917 oxazolidines Chemical group 0.000 description 1
TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
230000002688 persistence Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000026234 pro-estrus Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000757 progestagenic effect Effects 0.000 description 1
150000003146 progesterones Chemical class 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
208000023958 prostate neoplasm Diseases 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000004208 shellac Substances 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
102000005969 steroid hormone receptors Human genes 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
150000003673 urethanes Chemical class 0.000 description 1
235000012141 vanillin Nutrition 0.000 description 1
MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
239000000052 vinegar Substances 0.000 description 1
235000021419 vinegar Nutrition 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20004362A 1998-03-03 2000-09-01 S-substituerte 11<beta>-benzaldoksim-ostra-4,9-dien-karboksylsyretiolestere, fremgangsmate for deres fremstilling, farmasoytiske preparater inneholdende disse forbindelser, samt anvendelse av forbindelsene til fremstilling av medikamenter og prevensjonsmi NO316977B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19809845A DE19809845A1 (de)	1998-03-03	1998-03-03	S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
PCT/DE1999/000408 WO1999045023A1 (de)	1998-03-03	1999-02-10	S-SUBSTITUIERTE 11β-BENZALDOXIM-ESTRA-4,9-DIEN-KOHLENSÄURETHIOLESTER, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE VERBINDUNGEN ENTHALTENE PHARMAZEUTISCHE ZUBEREITUNGEN

Publications (3)

Publication Number	Publication Date
NO20004362D0 NO20004362D0 (no)	2000-09-01
NO20004362L NO20004362L (no)	2000-10-31
NO316977B1 true NO316977B1 (no)	2004-07-12

Family

ID=7860080

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20004362A NO316977B1 (no)	1998-03-03	2000-09-01	S-substituerte 11<beta>-benzaldoksim-ostra-4,9-dien-karboksylsyretiolestere, fremgangsmate for deres fremstilling, farmasoytiske preparater inneholdende disse forbindelser, samt anvendelse av forbindelsene til fremstilling av medikamenter og prevensjonsmi

Country Status (28)

Country	Link
US (1)	US6365582B1 (is)
EP (1)	EP1060187B1 (is)
JP (1)	JP3796405B2 (is)
KR (1)	KR100488823B1 (is)
CN (1)	CN1208341C (is)
AT (1)	ATE237627T1 (is)
AU (1)	AU749163B2 (is)
BG (1)	BG64735B1 (is)
BR (1)	BR9908458A (is)
CA (1)	CA2322471C (is)
CZ (1)	CZ20003125A3 (is)
DE (2)	DE19809845A1 (is)
DK (1)	DK1060187T3 (is)
EA (1)	EA002766B1 (is)
EE (1)	EE04242B1 (is)
ES (1)	ES2197634T3 (is)
HU (1)	HUP0100962A3 (is)
ID (1)	ID26972A (is)
IL (1)	IL137851A (is)
IS (1)	IS5579A (is)
NO (1)	NO316977B1 (is)
NZ (1)	NZ506048A (is)
PL (1)	PL193687B1 (is)
PT (1)	PT1060187E (is)
SK (1)	SK284177B6 (is)
TR (1)	TR200002506T2 (is)
UA (1)	UA59437C2 (is)
WO (1)	WO1999045023A1 (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19906152B4 (de)	1999-02-10	2005-02-10	Jenapharm Gmbh & Co. Kg	Wirkstoffhaltige Laminate für Transdermalsysteme
BR0013710A (pt) *	1999-08-31	2002-05-07	Jenapharm Gmbh	Mesoprogestinas (moduladores de receptor para progesterona) como um componente de composições para a terapia de reposição de hormÈnios (hrt)
US8193252B1 (en)	1999-08-31	2012-06-05	Bayer Pharma AG	Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
US7629334B1 (en) *	1999-08-31	2009-12-08	Bayer Schering Pharma Aktiengesellschaft	Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
UA77150C2 (en) *	1999-08-31	2006-11-15	Schering Ag	Use of mesoprogestins j867, j912, or j1042 for female contraception, pharmaceutical composition and kit (variants)
CA2382580C (en) *	1999-08-31	2009-05-19	Jenapharm Gmbh & Co. Kg	Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
EP1285927A3 (de) *	2001-08-16	2005-06-29	Schering Aktiengesellschaft	Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
DE10221034A1 (de) *	2002-05-03	2003-11-20	Schering Ag	17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
AU2003255355A1 (en) *	2002-08-02	2004-02-25	Schering Aktiengesellschaft	Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy
DE10236405A1 (de) *	2002-08-02	2004-02-19	Schering Ag	Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
DE102005059222B4 (de) *	2005-12-08	2007-10-11	Bayer Schering Pharma Ag	11ß-Benzaldoximderivate von D-Homoestra-4,9-dien-3-onen
HUE036870T2 (hu)	2006-10-24	2018-08-28	Repros Therapeutics Inc	Az endometriális proliferáció elnyomására szolgáló készítmények és módszerek
AU2008222829A1 (en) *	2007-03-07	2008-09-12	Janssen Pharmaceutica N.V.	Steroids derivatives as selective progesterone receptor modulators
TWI539953B (zh)	2008-04-28	2016-07-01	瑞波若斯治療學公司	用於治療乳癌之組成物和方法
DE102009034525A1 (de) *	2009-07-21	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
EP3865502A1 (en)	2010-03-22	2021-08-18	Allergan Pharmaceuticals International Limited	Compositions and methods for non-toxic delivery of cdb-2914
EP2664325A1 (en) *	2012-05-16	2013-11-20	PregLem S.A.	Methods for preventing or treating androgen mediated diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4039677A (en) *	1976-03-01	1977-08-02	Syntex (U.S.A.) Inc.	Novel 1-phenethylimidazoles
ZA8231B (en) *	1981-01-09	1982-11-24	Roussel Uclaf	New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
DE3504421A1 (de) *	1985-02-07	1986-08-07	Schering AG, 1000 Berlin und 4709 Bergkamen	Neue 11ss-phenyl-gonane, deren herstellung und diese enthaltende pharmazeutische praeparate
DE4332284C2 (de) *	1993-09-20	1997-05-28	Jenapharm Gmbh	11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) *	1993-09-20	1995-04-13	Jenapharm Gmbh	Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5576310A (en) *	1994-09-20	1996-11-19	Jenapharm Gmbh	11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
IL115738A (en)	1994-10-24	2002-05-23	Schering Ag	Competitive progesterone antagonists for regulating female fertility as required
ZA9510926B (en) *	1994-12-23	1996-07-03	Schering Ag	Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
KR100434238B1 (ko)	1995-03-14	2004-07-16	보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템	경관팽창및신장조절을위한산화질소공여체또는산화질소억제제의용도

1998
- 1998-03-03 DE DE19809845A patent/DE19809845A1/de not_active Ceased
1999
- 1999-02-10 NZ NZ506048A patent/NZ506048A/en unknown
- 1999-02-10 JP JP2000534565A patent/JP3796405B2/ja not_active Expired - Fee Related
- 1999-02-10 TR TR2000/02506T patent/TR200002506T2/xx unknown
- 1999-02-10 PT PT99915475T patent/PT1060187E/pt unknown
- 1999-02-10 EE EEP200000500A patent/EE04242B1/xx not_active IP Right Cessation
- 1999-02-10 ID IDW20001706A patent/ID26972A/id unknown
- 1999-02-10 ES ES99915475T patent/ES2197634T3/es not_active Expired - Lifetime
- 1999-02-10 PL PL99342449A patent/PL193687B1/pl unknown
- 1999-02-10 BR BR9908458-9A patent/BR9908458A/pt not_active Application Discontinuation
- 1999-02-10 AU AU34067/99A patent/AU749163B2/en not_active Ceased
- 1999-02-10 HU HU0100962A patent/HUP0100962A3/hu unknown
- 1999-02-10 DK DK99915475T patent/DK1060187T3/da active
- 1999-02-10 EA EA200000896A patent/EA002766B1/ru not_active IP Right Cessation
- 1999-02-10 US US09/622,803 patent/US6365582B1/en not_active Expired - Fee Related
- 1999-02-10 WO PCT/DE1999/000408 patent/WO1999045023A1/de not_active Ceased
- 1999-02-10 CA CA002322471A patent/CA2322471C/en not_active Expired - Fee Related
- 1999-02-10 IL IL13785199A patent/IL137851A/xx not_active IP Right Cessation
- 1999-02-10 AT AT99915475T patent/ATE237627T1/de not_active IP Right Cessation
- 1999-02-10 SK SK1305-2000A patent/SK284177B6/sk unknown
- 1999-02-10 CZ CZ20003125A patent/CZ20003125A3/cs unknown
- 1999-02-10 EP EP99915475A patent/EP1060187B1/de not_active Expired - Lifetime
- 1999-02-10 DE DE59905075T patent/DE59905075D1/de not_active Expired - Fee Related
- 1999-02-10 KR KR10-2000-7009712A patent/KR100488823B1/ko not_active Expired - Fee Related
- 1999-02-10 CN CNB998036080A patent/CN1208341C/zh not_active Expired - Fee Related
- 1999-10-02 UA UA2000105635A patent/UA59437C2/uk unknown
2000
- 2000-07-28 IS IS5579A patent/IS5579A/is unknown
- 2000-08-28 BG BG104712A patent/BG64735B1/bg unknown
- 2000-09-01 NO NO20004362A patent/NO316977B1/no unknown

Also Published As

Publication number	Publication date
IS5579A (is)	2000-07-28
DE19809845A1 (de)	1999-09-09
BR9908458A (pt)	2000-11-14
PL342449A1 (en)	2001-06-04
ID26972A (id)	2001-02-22
SK284177B6 (sk)	2004-10-05
US6365582B1 (en)	2002-04-02
EP1060187A1 (de)	2000-12-20
PL193687B1 (pl)	2007-03-30
CN1291990A (zh)	2001-04-18
EE04242B1 (et)	2004-02-16
DE59905075D1 (de)	2003-05-22
EE200000500A (et)	2002-02-15
BG64735B1 (bg)	2006-01-31
KR100488823B1 (ko)	2005-05-12
AU3406799A (en)	1999-09-20
HUP0100962A2 (hu)	2001-09-28
CZ20003125A3 (cs)	2002-01-16
SK13052000A3 (sk)	2001-11-06
IL137851A0 (en)	2001-10-31
JP3796405B2 (ja)	2006-07-12
NO20004362D0 (no)	2000-09-01
AU749163B2 (en)	2002-06-20
NO20004362L (no)	2000-10-31
IL137851A (en)	2005-06-19
PT1060187E (pt)	2003-09-30
ATE237627T1 (de)	2003-05-15
ES2197634T3 (es)	2004-01-01
HUP0100962A3 (en)	2002-07-29
CN1208341C (zh)	2005-06-29
EA002766B1 (ru)	2002-08-29
TR200002506T2 (tr)	2000-12-21
DK1060187T3 (da)	2003-08-11
CA2322471C (en)	2007-04-24
UA59437C2 (uk)	2003-09-15
NZ506048A (en)	2003-05-30
WO1999045023A1 (de)	1999-09-10
CA2322471A1 (en)	1999-09-10
JP2002505335A (ja)	2002-02-19
BG104712A (en)	2001-02-28
KR20010041536A (ko)	2001-05-25
EP1060187B1 (de)	2003-04-16
EA200000896A1 (ru)	2001-04-23

Publication	Publication Date	Title
NO316977B1 (no)	2004-07-12	S-substituerte 11<beta>-benzaldoksim-ostra-4,9-dien-karboksylsyretiolestere, fremgangsmate for deres fremstilling, farmasoytiske preparater inneholdende disse forbindelser, samt anvendelse av forbindelsene til fremstilling av medikamenter og prevensjonsmi
JP2753562B2 (ja)	1998-05-20	新規な１１−ベンズアルドキシム−エストラ−ジエン誘導体とその製造方法、及びその化合物を含有する医薬製剤
JP2696672B2 (ja)	1998-01-14	新規な１１−ベンズアルドキシム−１７β−メトキシ−１７α−メトキシメチル−エストラジエン誘導体、その製法およびその物質を含有する医薬製剤
AU8020887A (en)	1988-04-07	17 alpha-(substituted-methyl)-17 beta-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
US5576310A (en)	1996-11-19	11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
US7550451B2 (en)	2009-06-23	Progesterone receptor modulators with increased antigonadotropic activity for female birth control and hormone replacement therapy
JP2005539016A (ja)	2005-12-22	女性用受胎調節及びホルモン置換療法のための高められた抗ゴナドトロピン活性を有するプロゲステロン受容体モジュレーター
RU2137777C1 (ru)	1999-09-20	ПРОИЗВОДНЫЕ 11β-БЕНЗАЛЬДОКСИМ-ЭСТРА-4,9-ДИЕНА, СПОСОБ ИХ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
MXPA00007612A (en)	2002-06-05	S-SUBSTITUTED 11&bgr;-BENZALDOXIME-ESTRA-4,9-DIENE-CARBONIC ACID THIOLESTERS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS
HK1036071A (en)	2001-12-21	S-SUBSTITUTED 11β-BENZALDOXIME-ESTRA-4,9-DIENE-CARBONIC ACID THIOLESTERS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS
HK1120519A (en)	2009-04-03	Novel c18 modified retrosteroids as progesterone receptor modulator compounds